Merck begins Phase III ENHANCE-3 trial of Ohtuvayre in COPD
Merck & Co (MSD) has started the Phase III ENHANCE-3 trial for Ohtuvayre (ensifentrine) to prevent COPD exacerbations. The study aims to enroll 2,136 patients across 28 countries, with primary endpoints assessing exacerbation rates over 52 weeks. Ohtuvayre was approved by the FDA in June 2024 for COPD maintenance.
How this was made
The 30-second read
Why it matters
Successful Phase III data could support expanded indications and boost Merck's respiratory franchise, while failure could dampen expectations.
Market read
First‑report of a pivotal Phase III trial for a marketed COPD drug; modest immediate trading relevance but important long‑term catalyst.
What to watch
The trial size (2,136 patients) and global enrollment could affect timelines; competition from other COPD therapies may dilute impact.
Background
Merck's Ohtuvayre was FDA‑approved in 2024 for COPD maintenance; the Phase III trial aims to confirm efficacy in reducing exacerbations.
Ticker impact
Merck & Co (MSD) announced the start of its Phase III ENHANCE-3 trial for Ohtuvayre in COPD, the first report of this trial initiation.
neutral to slight upside as investors price in potential future approval
Phase III initiation is a material development for a large pharma, yet no near‑term revenue or regulatory outcome is known, so market reaction is likely muted.
Market effects
Adds to the pipeline momentum in the respiratory therapeutics sector, may boost sector sentiment if trial progresses positively.
US biotech investors may monitor the trial, but limited broader regional effect.
Potential global relevance for COPD treatment markets if data prove positive.
Counterpoint
If the trial encounters setbacks, Merck could face a negative re‑rating, making the stock vulnerable.
Key entities
- companyMerck & Co
US‑listed pharmaceutical company (ticker MRK) launching Phase III trial.
- drugOhtuvayre (ensifentrine)
COPD maintenance therapy under investigation.
